Generic Exclusivity Usefulness Needs Review, FDA's Dickinson Says
This article was originally published in The Tan Sheet
Executive Summary
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson said at the Food & Drug Law Institute's Hatch/Waxman conference in Washington, D.C. Dec. 11.
You may also be interested in...
Sens. McCain, Schumer Sponsor Generic Drug Approval Acceleration Bill
Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) intend to rally support in the next session of Congress for legislation introduced Sept. 14 that would ease the FDA approval process for generic drugs.
180-Day Exclusivity Must Begin Within 180-Day "Triggering Period" - FDA
Generic drug firms eligible for 180 days of marketing exclusivity would lose their eligibility if the exclusivity period were not triggered within 180 days of tentative approval of another ANDA referencing the same listed drug. FDA spells out this condition in an Aug. 6 proposed rule.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC